创新药再迎重大利好：两部委发布若干措施，全链条支持创新药发展

Group 1 - The core viewpoint of the news is the release of the "Several Measures to Support the High-Quality Development of Innovative Drugs," which aims to enhance support for innovative drug research and development through various initiatives [1][3]. - The measures include 16 specific actions across five areas, such as increasing R&D efforts, supporting innovative drugs' inclusion in basic medical insurance and commercial health insurance directories, and improving clinical application and payment capabilities [4][5]. - The approval of 41 first-class innovative drugs by the National Medical Products Administration this year indicates a significant rise in domestic pharmaceutical companies' capabilities, with over 85% of these drugs being developed by Chinese firms [2][3]. Group 2 - The "Several Measures" are a refinement of the "Full Chain Support Plan for Innovative Drug Development," which was established to address current challenges in the innovative drug sector [3][4]. - The introduction of a dynamic adjustment mechanism for the medical insurance directory allows most innovative drugs to be included within two years of market launch, while the new commercial health insurance directory provides alternative payment channels for innovative drugs [5][6]. - The measures aim to address the entire lifecycle of innovative drugs, tackling issues related to R&D, payment, and clinical access, thereby attracting more capital and talent to the innovative drug sector [6].